Given what we know about the safety of PCSK9 inhibitors and the risk of recurrent events in patients who have experienced an ACS,

Given what we know about the safety of PCSK9 inhibitors and the risk of recurrent events in patients who have experienced an ACS,

are there any risk signatures that compel a lipid specialist to consider using a PCSK9 inhibitor early in the patient’s course?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Alberico Catapano, PhD

Alberico Catapano, PhD

Full Professor of Pharmacology University of Milano Director, Laboratory for the Study of Lipoproteins and Atherosclerosis Director, Center for the Study of Atherosclerosis of the Italian Society of Atherosclerosis